Expansion momentum Sino Biological shows active growth with multiple new offerings and launches in 2025–2026, including SuperNuclease Pro, XPressMAX Cell-Free Protein Synthesis Kit, SwiftFluo TR-FRET kits, and high-purity NiV proteins, signaling opportunities to cross-sell advanced reagents and integrated solutions to biotech labs and drug discovery teams.

Strategic collaborations Operates Central R&D and partnerships via centers like Center for Bioprocessing in Houston and SignalChem Biotech in Vancouver, positioning Sino Biological as a partner for contract research, process development, and therapeutic discovery collaborations in mammalian production and kinase research.

Tech-led offerings Portfolio emphasizes cutting-edge tools for high-throughput discovery and diagnostics—cell-free synthesis kits, TR-FRET kinase assays, nuclease solutions, and recombinant proteins—creating cross-sell potential to labs adopting AI-driven screening and rapid protein development.

Awards and credibility Recent industry recognition (Scientist.com supplier awards) enhances credibility with procurement teams, helping to shorten sales cycles and justify multi-year partnerships for CRO services, protein production, and reagent supply.

Market positioning Mid-size global biotech supplier with $100–$250M revenue and a growing product suite targets academic and industrial research buyers seeking high-quality recombinant proteins, antibodies, and discovery tools, presenting an opportunity to expand into viral proteins, diagnostics reagents, and kinase research demands.